Icon (NASDAQ:ICLR) Stock: Insider Emer Lyons Sells 272 Shares

Icon Plc (NASDAQ:ICLR) CAO Emer Lyons sold 272 shares of the company’s stock in a transaction that occurred on Friday, October 23rd. The stock was sold at an average price of $182.37, for a total transaction of $49,604.64. Following the completion of the sale, the chief accounting officer directly owned 990 shares of the company’s stock, valued at approximately $180,546.30. This represents a 21.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Icon Trading Down 0.4%

Icon stock opened at $182.98 on Wednesday. The firm has a 50 day simple moving average of $169.42 and a 200-day simple moving average of $146.06. Icon Plc has a 12-month low of $66.57 and a 12-month high of $203.91.

Icon (NASDAQ:ICLR) last released its earnings results on Tuesday, October 27th. The medical research company reported $2.66 earnings per share for the quarter, topping analysts’ consensus estimates of $2.62 by $0.04. The firm had revenue of $2.02 billion during the quarter, compared to analyst estimates of $2.01 billion. The business’s revenue for the quarter was down .9% on a year-over-year basis. During the same quarter last year, the company earned $3.31 earnings per share. As a group, equities analysts predict that Icon Plc will post 9.55 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on ICLR shares. William Blair raised Icon to a “strong-buy” rating in a research note on Thursday, July 30th. Truist Financial reaffirmed a “buy” rating and set a $209.00 target price (up from $207.00) on shares of Icon in a report on Friday, July 31st. Bank of America upgraded shares of Icon from an “underperform” rating to a “neutral” rating and set a $185.00 price target on the stock in a research report on Friday, October 9th. Robert W. Baird set a $194.00 price target on shares of Icon in a report on Friday, July 31st. Finally, UBS Group began coverage on shares of Icon in a research report on Wednesday, September 30th. They set a “neutral” rating and a $195.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Icon currently has a consensus rating of “Hold” and an average price target of $174.73.

Icon News Summary

Here are the key news stories impacting Icon this week:

• Positive Sentiment: ICON earned $2.66 per share, ahead of the $2.62–$2.64 consensus range, while revenue of $2.02 billion also exceeded the approximately $2.01 billion estimate. The beat may support investor confidence in the contract research organization’s execution. ICON Q3 earnings and revenue beat estimates
• Positive Sentiment: A reported $24.5 billion backlog and a raised buyback signal point to substantial future demand and potential shareholder returns, strengthening the company’s longer-term recovery narrative. ICON Q3 2026 earnings and backlog
• Neutral Sentiment: ICON’s short-interest data showed no reported shares sold short as of October 26, implying limited evidence of bearish positioning, although the figure provides little direct catalyst for the stock.
• Neutral Sentiment: Chief Accounting Officer Emer Lyons sold 272 shares for about $49,600 to cover tax withholding tied to vested equity awards. Because the transaction was tax-related and relatively small, it is less concerning than a discretionary insider sale.
• Negative Sentiment: Quarterly EPS fell from $3.31 to $2.66 year over year, while revenue declined 0.9%. ICON’s net margin was only 3.99%, highlighting continuing profitability pressure despite the estimates beat.
• Negative Sentiment: The analyst consensus remains “Hold”, with an average price target of $174.73—below the recently cited trading level—suggesting valuation concerns and limited near-term upside.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Verdence Capital Advisors LLC bought a new stake in shares of Icon during the 3rd quarter worth $571,000. Pullen Investment Management LLC acquired a new position in shares of Icon in the 3rd quarter worth $907,000. Gibbs Wealth Management acquired a new position in shares of Icon in the 3rd quarter worth $235,000. Inspire Investing LLC raised its position in shares of Icon by 8.4% during the third quarter. Inspire Investing LLC now owns 18,625 shares of the medical research company’s stock worth $3,166,000 after purchasing an additional 1,443 shares during the period. Finally, Parthenon LLC raised its position in shares of Icon by 1.2% during the third quarter. Parthenon LLC now owns 79,603 shares of the medical research company’s stock worth $13,532,000 after purchasing an additional 950 shares during the period. Institutional investors own 95.61% of the company’s stock.

Icon Company Profile

ICON plc is a global contract research organization that provides outsourced development services to pharmaceutical, biotechnology and medical device companies. The company supports clinical research programs from early development through late-stage trials, regulatory submission and post-marketing activities.

Its services include clinical trial management, medical and regulatory consulting, biostatistics, data management, pharmacovigilance, laboratory services and real-world evidence solutions.